Lymphoseek bests standard dye, researchers find

03/25/2013 | News-Medical.Net

The recently approved radioactive agent Lymphoseek, technetium Tc-99m tilmanocept, was able to detect cancerous lymph nodes and performed better than the standard agent in identifying cancers, according to findings published in the Annals of Surgical Oncology. Researchers found that more than 99% of sentinel lymph nodes with standard dye uptake also had Lymphoseek. Lymphoseek identified 94% of malignancies, compared with 76% for the standard blue dye. "This could standardize the process of lymph node mapping and make the process easier, particularly for less experienced surgeons," said principal investigator Dr. Anne Wallace from the University of California, San Diego.

View Full Article in:

News-Medical.Net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA